Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats

• Published in: Brain research Vol. 743; no. 1-2; pp. 124 - 130
• Main Authors: Pollack, A E, Fink, J S
• Format: Journal Article
• Language: English
• Published: Netherlands 16-12-1996
• Subjects: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology; Animals; Corpus Striatum - drug effects; Corpus Striatum - metabolism; Dopamine Agonists - pharmacology; Drug Synergism; Functional Laterality - physiology; Male; Motor Activity - drug effects; Neurotoxins; Oxidopamine; Proto-Oncogene Proteins c-fos - biosynthesis; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 - agonists; Rotation; Theobromine - analogs & derivatives; Theobromine - pharmacology
• ISSN: 0006-8993
• DOI: 10.1016/S0006-8993(96)01036-0

The interaction between adenosine and D1 dopamine systems in regulating motor behavior and striatal c-Fos expression was examined in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions. These results were compared to the synergistic interaction between D1 and D2 dopamine systems in 6-OHDA rats. Coadministration of the adenosine antagonist 3,7-dimethyl-1-propargylxanthine (DMPX: 10 mg/kg) and the D1 dopamine agonist SKF38393 (0.5 mg/kg) to 6-OHDA-lesioned rats produced significant contralateral rotation and c-Fos expression in the ipsilateral striatum compared to 6-OHDA rats treated with either drug alone. However, the regional pattern of striatal c-Fos activation following treatment of 6-OHDA rats with SKF38393 and DMPX was different from the dorsolateral pattern of striatal c-Fos induction observed after coadministration of D1 and D2 dopamine agonists (SKF38393: 0.5 mg/kg + quinpirole: 0.05 mg/kg). These data are consistent with a functional interaction between D1 dopamine and adenosine systems in the striatum, but suggest that activation of different subsets of striatal neurons underlie the behavioral synergy observed following combined adenosine antagonist-D1 dopamine agonist and combined D1 dopamine agonist-D2 dopamine agonist treatment.